Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: Potential role in promoting cytotoxic drug action

Clinical Cancer Research

Volumn 7, Issue 4, 2001, Pages 775-783

  Dent, P ^a   Grant, S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BRYOSTATIN 1; CAMPTOTHECIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; GYRASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; SAFINGOL; TAXANE DERIVATIVE; VINBLASTINE;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE C; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 0034907636     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (97)

1. The stress-activated protein kinase pathways
2. Serine/threonine protein kinases and apoptosis
3. MAP kinase pathways
4. Dual potential of extracellular signal-regulated kinase for the control of cell survival
5. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/ JNK and p38 signaling pathways
6. MAP kinase-dependent pathways in cell cycle control
7. Muscle proteins related to microtubule associated protein-2 are substrates for an insulin-stimulatable kinase
8. Identification of multiple extracellular signal-regulated kinases (ERKs) with antipeptide antibodies
9. Insulinstimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II
10. Renaturation and partial peptide sequencing of mitogen-activated protein kinase (MAP kinase) activator from rabbit skeletal muscle
11. Functional expression of a MAP kinase in COS cells and recognition by an anti-STE7/byrl antibody
12. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro
13. RIP2 is a Raflactivated mitogen-activated protein kinase kinase
14. The complexity of Raf-1 regulation
15. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1
16. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases
17. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
18. Regulation of Raf-1 and Raf-1 mutants by distinct GTP-dependent and GTP-independent mechanisms in vitro
19. A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity
20. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C
21. Forskolin inhibits protein kinase C-induced mitogen activated protein kinase activity in MC3T3-E1 osteoblasts
22. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling
23. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis
24. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis
25. The extended protein kinase C superfamily
26. Rescue from programmed cell death in leukemic and normal myeloid cells
27. Induction of a common pathway of apoptosis by staurosporine
28. Modulation of 1-[β-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C
29. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin
30. Bryostatin 1 and phorbol ester down-modulate protein kinase C-α and -ε via the ubiquitin/proteasome pathway in human fibroblasts
31. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-β-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2
32. Phase Ib trial of bryostatin 1 in patients with refractory malignancies
33. Protein kinase C targeting in antineoplastic treatment strategies
34. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-β-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling
35. 12-O-Tetradecanoyl phorbol 13-acetate, protein kinase C (PKC) activator, protects human leukemia HL-60 cells from Taxol-induced apoptosis: Possible role for extracellular signal-regulated kinase
36. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
37. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
38. The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo
39. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
40. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
41. Prevention of apoptosis by Bcl-2: Release of cytochrome c from mitochondria blocked
42. Caspases: The executioners of apoptosis
43. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
44. The biochemistry of apoptosis
45. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway
46. Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Racl
47. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
48. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53
49. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells
50. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation
51. MAPK-dependent expression of p21(WAF) and p27(kip1) in PMA-induced differentiation of HL60 cells
52. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)
53. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation
54. Impact of the cyclindependent kinase inhibitor p27Kip1 on resistance of tumor cells to anficancer agents
55. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-κB through IκB kinase-α and IκB kinase-β
56. The pro- or anti-apoptotic function of NF-κB is determined by the nature of the apoptotic stimulus
57. Suppression of TNF-α-induced apoptosis by NF-κB
58. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
59. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms
60. Inactivation of Bcl-2 by phosphorylation
61. A functional role for mitochondrial protein kinase Cα in Bcl2 phosphorylation and suppression of apoptosis
62. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases
63. Rb function in cell-cycle regulation and apoptosis
64. A MAP kinase-dependent spindle assembly checkpoint in Xenopus egg extracts
65. The mitogen-activated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes
66. Functional consequences of the 1-β-D-arabinofuranosylcytosine structural lesion in DNA
67. Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells
68. 1-β-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells
69. c-Abl activation regulates induction of the SEK1/stress-activated protein kinase pathway in the cellular response to 1-β-D-arabinofuranosylcytosine
70. Protein kinase C βII activation by 1-β-D-arabinofuranosylcytosine is antagonistic to stimulation of apoptosis and Bcl-2 down-regulation
71. Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells
72. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-β-D-arabinofuranosylcytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells
73. Bryostatins selectively regulate protein kinase C-mediated effects on GH4 cell proliferation
74. A role for MAPK/ERK in sympathetic neuron survival: Protection against a p53-dependent, JNK-independent induction of apoptosis by 1-β-D-arabinofuranosylcytosine
75. Role of c-Jun N-terminal kinase/p38 stress signaling in 1-β-D-arabinofuranosylcytosine-induced apoptosis
76. Mechanism of action of Taxol
77. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells
78. Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells
79. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
80. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells
81. Serine protease inhibitor TPCK prevents Taxol-induced cell death and blocks c-Raf-1 and Bcl-2 phosphorylation in human breast carcinoma cells
82. 2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts
83. Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells
84. Mitogen-activated protein kinase kinase activity is required for the G(2)/M transition of the cell cycle in mammalian fibroblasts
85. Role of mitogen-activated protein kinase in Taxol-induced apoptosis in human leukemic U937 cells
86. Effect of bryostatin 1 on Taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937)
87. MEK inhibition enhances paclitaxel-induced tumor apoptosis
88. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis
89. Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells
90. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: Inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin
91. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin
92. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line
93. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin
94. MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes
95. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells
96. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase
97. Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C